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ARTICLE OPEN
Health status instruments for patients with COPD in
pulmonary rehabilitation: deﬁning a minimal clinically
important difference
Harma Alma1, Corina de Jong1, Danijel Jelusic2, Michael Wittmann2, Michael Schuler3, Bertine Flokstra-de Blok1, Janwillem Kocks1,
Konrad Schultz2 and Thys van der Molen1
The minimal clinically important difference (MCID) deﬁnes to what extent change on a health status instrument is clinically relevant, which
aids scientists and physicians in measuring therapy effects. This is the ﬁrst study that aimed to establish the MCID of the Clinical chronic
obstructive pulmonary disease (COPD) Questionnaire (CCQ), the COPD Assessment Test (CAT) and the St George’s Respiratory
Questionnaire (SGRQ) in the same pulmonary rehabilitation population using multiple approaches. In total, 451 COPD patients participated
in a 3-week Pulmonary Rehabilitation (PR) programme (58 years, 65% male, 43 pack-years, GOLD stage II/III/IV 50/39/11%). Techniques
used to assess the MCID were anchor-based approaches, including patient-referencing, criterion-referencing and questionnaire-
referencing, and the distribution-based methods standard error of measurement (SEM), 1.96SEM and half standard deviation (0.5s.d.).
Patient- and criterion-referencing led to MCID estimates of 0.56 and 0.62 (CCQ); 3.12 and 2.96 (CAT); and 8.40 and 9.28 (SGRQ).
Questionnaire-referencing suggested MCID ranges of 0.28–0.61 (CCQ), 1.46–3.08 (CAT) and 6.86–9.47 (SGRQ). The SEM, 1.96SEM and 0.5s.d.
were 0.29, 0.56 and 0.46 (CCQ); 3.28, 6.43 and 2.80 (CAT); 5.20, 10.19 and 6.06 (SGRQ). Pooled estimates were 0.52 (CCQ), 3.29 (CAT) and
7.91 (SGRQ) for improvement. MCID estimates differed depending on the method used. Pooled estimates suggest clinically relevant
improvements needing to exceed 0.40 on the CCQ, 3.00 on the CAT and 7.00 on the SGRQ for moderate to very severe COPD patients. The
MCIDs of the CAT and SGRQ in the literature might be too low, leading to overestimation of treatment effects for patients with COPD.
npj Primary Care Respiratory Medicine (2016) 26, 16041; doi:10.1038/npjpcrm.2016.41; published online 1 September 2016
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is the third leading
cause of death.1 Spirometry is required to make the diagnosis.2 Its
parameter forced expiratory volume in 1 s (FEV1) has, however, a
weak correlation with symptoms and disease impact, which are
factors captured by health status instruments.3 Health status has
become an important goal in the management of COPD.2 Multiple
instruments exist that measure health status with the Clinical COPD
Questionnaire (CCQ), COPD Assessment Test (CAT) and St. George’s
Respiratory Questionnaire (SGRQ) most frequently used.4–6 These
tools are important in assessing treatment effectiveness. Therefore,
clinically relevant change as an outcome of the questionnaires has
become pivotal. The minimal clinically important difference (MCID) is
a parameter that assesses clinically relevant change. It is deﬁned as
‘the smallest difference in score, which patients perceive as beneﬁcial
and which would mandate a change in the patient’s management’.7
Multiple methods for determining the MCID exist, clustered into
anchor-based and distribution-based approaches.8–10 Anchor-
based approaches require change in health status to be compared
with another measure of clinical change, such as a global rating of
change (GRC) assessment (patient-referencing); the appearance of
health events in the time of change (criterion-referencing); and/or
a related instrument with known MCID (questionnaire-
referencing).8 Distribution-based methods require comparison of
change with a statistical measure of variability of this change, such
as the standard error of measurement (SEM) or half the s.d.
(0.5s.d.).8,11,12 Anchor-based methods are preferred, as they
convey clinical signiﬁcance, yet distribution-based approaches
are quicker to use.9,10 A golden standard has not been deﬁned.
Different methods will lead to a range of estimates.8,10,13 A
pledge has been made for an overall body of evidence to agree
upon an MCID or to use multiple in practice.8,10,13,14 This body of
evidence should consist of relevant patient-reported anchors and
clinical trial data.10,15 However, selecting appropriate anchors is
problematic, since this commonly used method is highly
dependent on the correlation between instruments (preferably
⩾0.50) as well as the accuracy of the anchor instrument’s MCID.10,15
Existing evidence for the MCID of the CCQ suggests a value of
0.40, which is equivalent to 7% of the scale (range: 0–6).16–19 The
anchor-based methods patient-referencing, criterion-referencing
and questionnaire-referencing, with the SGRQ, CAT and chronic
respiratory questionnaire (CRQ) as anchors, were separately
applied in either a Dutch prednisolone trial following acute
exacerbation, in pulmonary rehabilitation (PR) for both COPD and
non-COPD patients or in a Greek primary and secondary care
population.16–18 The SEM and 0.5s.d. techniques were applied
too.17–19 None of the studies combined all of the approaches in
the same COPD population. The MCID for the domain scores on
the CCQ has not been established either.
The MCID of the CAT was summarised into two points,
equivalent to 5% of the scale (range: 0–40).5,19–21 Both anchor-
based and distribution-based techniques were applied in a PR
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setting, for acute exacerbation COPD patients and for outpatients.
Criterion-referencing has not been speciﬁcally applied for the CAT,
nor have all methods been applied simultaneously.
The MCID for the SGRQ is set at four points, which is 4% of the
scale (range: 0–100).6,22,23 Expert-based ratings, patient-referen-
cing, criterion-referencing and the use of the 6-min walking
distance (6MWD) and the CRQ as anchors have been applied in
various studies on asthma and COPD patients. These studies are
from many years ago; therefore, a recent study on severe COPD
patients, who underwent bronchoscopic lung volume reduction,
claimed the MCID of the SGRQ to be 47 points.24 It used FEV1,
6MWD and residual volume as anchors combined with
distribution-based methods. Estimates on the MCID of the SGRQ
seem inconsistent. None of the methods have been applied at
once, nor is the MCID of domain scores of the SGRQ investigated.
The MCIDs of health status tools are necessary for physicians
and researchers to evaluate therapy results and clinical trials.
Expanding the body of evidence for the MCID remains of major
importance. This study is the ﬁrst study to investigate the MCID of
the CCQ, CAT and SGRQ simultaneously in pulmonary rehabilita-
tion (PR) using the largest array of methods. It examines the
impact of using anchors and distribution-based methods to
determine an instrument’s MCID. The domain scores on the CCQ
and SGRQ are investigated for their MCID as well, which is a new
development.
RESULTS
Patient characteristics and health status
In total, 611 patients participated in the RIMTCORE trial, among
whom 50 discontinued the study.25 Out of the remaining
participants, 451 met the inclusion criteria for the current MCID
study. Mean age was 57.87 ± 6.56 years, 65% were male and
50/39/11% were GOLD II/III/IV (Table 1). CCQ, CAT and SGRQ were
normally distributed at T0 and T1; change scores were normally
distributed for CCQ, CAT and SGRQ symptom scores. Floor and
ceiling effects were negligible, except for the CCQ mental domain.
There were no missing health status questionnaires at T0. There
were four missing participants for the SGRQ, 1 for the CCQ and 2
for the CAT at T1. Pair-wise deletion was applied. Mean baseline
scores were 2.86 ± 1.17 (CCQ), 20.23 ± 7.33 (CAT) and 50.69 ± 17.33
(SGRQ), with signiﬁcant improvement after PR of, respectively, 0.58
(95% conﬁdence interval (CI) 0.50–0.67), 3.11 (95% CI 2.59–3.63)
and 9.04 (95% CI 7.92–10.17; Table 2).
MCID: patient-referencing
A GRC score was missing for one patient. Correlations between
GRC and health status instruments were signiﬁcant, with r= 0.29
(CCQ), 0.23 (CAT) and 0.30 (SGRQ). In total, 12 patients showed
deterioration on the GRC (GRC⩽− 2). No, or hardly any,
improvement (GRC = 0, or +1) was experienced by 21.7%
(n= 98). Minimal improvement (GRC=+2 and +3) was seen in
43.5% of patients (n= 196), whereas moderate (GRC =+4 and +5)
and major improvements (GRC=+6 and +7) represented,
respectively, 27.3% (n= 123) and 5.5% (n= 25; Table 3). At the
threshold for minimal clinically relevant improvement (GRC=+2
or +3), mean CCQ, CAT and SGRQ change scores were,
respectively, 0.56 (95% CI 0.44–0.68), 3.12 (95% CI 2.37–3.86)
and 8.40 (95% CI 6.73–10.07). Mean improvements for these
patients on the CCQ domains were 0.55 (symptoms), 0.55
(functional) and 0.58 (mental), and for the SGRQ domains they
were 13.12 (symptoms), 5.98 (activity) and 8.24 (impact).
MCID: criterion-referencing
During PR, 10% of patients (n= 45) experienced an exacerbation.
There were no missing data. Mean differences between both
groups at baseline were 0.62 (95% CI 0.27–0.98) for CCQ, 2.96 (95%
CI 0.71–5.20) for CAT and 9.28 (95% CI 3.99–14.56) for SGRQ, with
signiﬁcantly higher scores for patients with an exacerbation.
Signiﬁcant domain differences were 0.47, 0.67 and 0.86 for the
respective CCQ symptoms, functional and mental domains; and
10.61 and 9.93 for the SGRQ activity and impact domains.
MCID: questionnaire-referencing
Signiﬁcant correlations between total change scores were 0.63
(SGRQ versus CCQ), 0.54 (SGRQ versus CAT) and 0.59 (CCQ versus
CAT; Supplementary Table 1, online supplement). Using the original
Table 1. Baseline characteristics
Baseline
Age (years)a 57.87± 6.56
BMIa 26.82± 6.56
Gender (male)b 65.0 (n=293)
FEV1%pred
a 50.40± 15.11
GOLD IIb 227 (50.3)
GOLD IIIb 176 (39.0)
GOLD IVb 48 (10.6)
Smoking pack-yearsa 42.61± 23.47
Never smokersb 6 (1.3)
Active smokersb 179 (39.7)
Ex-smokersb 266 (59.0)
Retiredb 74 (16.4)
If not retired, unable to workb 159 (35.3)
Patients with ⩾ 1 exacerbation(s) during the past
12 months before PRb
353 (78.4)
N= 451.
Abbreviations: BMI, body mass index; FEV1%pred, forced expiratory
volume in 1 s % predicted; GOLD, global initiative for chronic obstructive
lung disease; PR, pulmonary rehabilitation.
aData were expressed as mean± s.d.
bData were expressed as frequencies (% of total patients).
Table 2. Health status outcomes of pulmonary rehabilitation
Instrument Baselinea Changea 95% CIb
CCQ
Symptoms 2.87± 1.24 − 0.59± 1.16 − 0.70 to − 0.48
Functional 2.86± 1.34 − 0.56± 1.00 − 0.65 to − 0.46
Mental 2.86± 1.74 − 0.62± 1.49 − 0.76 to − 0.48
Total 2.86± 1.17 − 0.58± 0.92 − 0.67 to − 0.50
CAT
Total 20.23± 7.33 − 3.11± 5.59 − 3.63 to − 2.59
SGRQ
Symptoms 63.66± 21.77 − 14.22± 21.69 − 16.24 to − 12.21
Activities 63.58± 19.82 − 6.71± 13.44 − 7.96 to − 5.47
Impact 39.21± 18.81 − 8.78± 13.95 − 10.08 to − 7.49
Total 50.69± 17.33 − 9.04± 12.11 − 10.17 to − 7.92
6MWD 427.73± 110.18 80.19± 54.72 75.01–85.37
N= 451.
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Ques-
tionnaire; COPD, chronic obstructive pulmonary disease; mMRC, modiﬁed
Medical Research Council Dyspnoea Scale; SGRQ, St George’s Respiratory
Questionnaire; 6MWD, 6-min walking distance; 95% CI, 95% conﬁdence
interval;.
aData were expressed as mean± s.d. Negative change represents
improvement on the CCQ, CAT and SGRQ.
bPaired t-tests were applied for the normally distributed data, Wilcoxon
signed-rank tests for non-parametric data. All tests were signiﬁcant with
Po0.05 comparing pre- and post-pulmonary rehabilitation scores.
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anchor estimates from the literature (CCQ=0.40, CAT=2.00
and SGRQ=4.00), the various questionnaire-referencing results
including 95% CI resulted in the following ranges: 0.42–0.53
(CAT as anchor) and 0.28–0.50 (SGRQ as anchor) for CCQ;
2.14–3.00 (CCQ as anchor) and 1.46–3.00 (SGRQ as anchor) for
CAT; and 6.86–8.30 (CCQ as anchor) and 6.98–8.48 (CAT as anchor)
for SGRQ (Table 4, see also Supplementary ﬁgures 1-6 of the online
supplement). Using averaged estimates from the other MCID
approaches in this study (CCQ=0.50, CAT=3.00 and SGRQ=7.00),
the results including 95% CI are 0.53–0.61 (CAT as anchor) and 0.44–
0.60 (SGRQ as anchor) for CCQ; 2.54–3.08 (CCQ as anchor) and 2.32–
3.00 (SGRQ as anchor) for CAT; and 7.79–8.90 (CCQ as anchor) and
8.00–9.47 (CAT as anchor) for SGRQ (Table 4, see also Supplementary
ﬁgures 1-6 of the online supplement).
MCID: distribution-based approach
The SEM for the CCQ, CAT and SGRQ was 0.29, 3.28 and 5.20,
respectively; the 1.96SEM was 0.56, 6.43 and 10.19, respectively;
and the 0.5s.d. was 0.46, 2.80 and 6.06, respectively.
Table 3. MCID patient-referencing results
Instrument No/hardly any improvement
(GRC 1, 0 or +1) N= 98
Minimal improvement (GRC +2
or +3) N= 196
Moderate improvement (GRC
+4 or +5) N= 123
Major improvement (GRC +6 or
+7) N= 25
Δa 95% CIb Δa 95% CIb Δa 95% CIb Δa 95% CIb
CCQ
Symptoms − 0.32 − 0.54 to − 0.10 − 0.55 − 0.70 to − 0.40 − 0.76 − 0.96 to − 0.56 − 1.48 − 1.97 to − 0.99
Functional − 0.27 − 0.47 to − 0.07 − 0.55 − 0.68 to − 0.43 − 0.78 − 0.98 to − 0.58 − 0.97 − 1.31 to − 0.63
Mental − 0.53 − 0.84 to − 0.22 − 0.58 − 0.78 to − 0.38 − 0.67 − 0.94 to − 0.39 − 1.34 − 1.84 to − 0.84
Total − 0.34 − 0.52 to − 0.15 − 0.56 − 0.68 to − 0.44 − 0.75 − 0.92 to − 0.58 − 1.25 − 1.54 to − 0.96
CAT
Total − 2.05 − 3.13 to − 0.98 − 3.12 − 3.86 to − 2.37 − 3.67 − 4.70 to − 2.67 − 6.44 − 8.99 to − 3.89
SGRQ
Symptoms − 7.03 − 10.86 to − 3.19 − 13.12 − 16.05 to − 10.19 − 19.91 − 23.92 to − 15.90 − 30.62 − 38.40 to − 22.84
Activities − 3.03 − 5.28 to − 0.78 − 5.9 − 7.88 to − 4.08 − 10.33 − 12.78 to − 7.87 − 12.66 − 18.69 to − 6.62
Impact − 6.72 − 9.57 to − 3.86 − 8.24 − 10.14 to − 6.33 − 10.32 − 12.77 to − 7.87 − 17.90 − 23.64 to − 12.16
Total − 5.57 − 7.79 to − 3.35 − 8.40 − 10.07 to − 6.73 − 11.83 − 14.00 to − 9.66 − 18.50 − 22.81 to −14.18
Abbreviations: CAT, COPD assessment test; CCQ, Clinical COPD Questionnaire; CI, conﬁdence interval; GRC, global rating of change; MCID, minimal clinically
important difference; SGRQ, St. George’s Respiratory Questionnaire; Δ, change score; 95% CI, 95% conﬁdence interval.
aData were reported as mean change scores. Negative change represents improvement for all instruments.
bPaired t-tests were applied to normally distributed variables, and Wilcoxon signed-rank tests were used for not normally distributed data. Data were reported
as 95% CI. All change scores were signiﬁcant with P-value o0.05.
Table 4. MCID questionnaire-referencing results
Anchor CCQ=0.40 Anchor CCQ= 0.50 Anchor CAT= 2 Anchor CAT= 3 Anchor SGRQ= 4 Anchor SGRQ= 7
Regression analysis
CCQ — — 0.48 (0.42–0.53) 0.57 (0.53–0.61) 0.34 (0.28–0.40) 0.48 (0.44–0.53)
CAT 2.45 (2.14–2.77) 2.81 (2.54–3.08) — — 1.86 (1.46–2.27) 2.61 (2.32–2.91)
SGRQ 7.51 (6.86–8.16) 8.35 (7.79–8.90) 7.73 (6.98–8.48) 8.89 (8.31–9.47) — —
Failing/achieving
CCQ — — 0.48 0.56 0.46 0.53
CAT 2.74 2.82 — — 2.45 2.86
SGRQ 8.14 8.36 7.78 8.69 — —
ROC curves
CCQ — — 0.50 0.60 0.50 0.60
AUC 0.767 AUC 0.771 AUC 0.796 AUC 0.802
Sens 0.701 Sens 0.716 Sens 0.750 Sens 0.763
Spec 0.706 Spec 0.710 Spec 0.714 Spec 0.730
CAT 3.00 3.00 — — 3.00 3.00
AUC 0.768 AUC 0.770 AUC 0.722 AUC 0.737
Sens 0.726 Sens 0.729 Sens 0.727 Sens 0.705
Spec 0.656 Spec 0.668 Spec 0.605 Spec 0.650
SGRQ 8.30 8.63 7.50 8.00 — —
AUC 0.817 AUC 0.816 AUC 0.719 AUC 0.745
Sens 0.777 Sens 0.787 Sens 0.659 Sens 0.673
Spec 0.703 Spec 0.702 Spec 0.656 Spec 0.681
Data are expressed as estimates (95% CI).
N= 451;
Abbreviations: AUC, area under the curve; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; ROC,
receiver operating characteristics curves; Sens, Sensitivity; Spec, Speciﬁcity; SGRQ, St. George’s Respiratory Questionnaire; 95% CI, 95% conﬁdence interval.
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Figure 1. (a–c) Summary plots of the CCQ, CAT and SGRQ MCID estimates. The horizontal plots represent the MCID estimates derived in this
study, classiﬁed per method. Where appropriate the estimates include the 95% conﬁdence interval. The red vertical line resembles the MCID
estimate as obtained from the literature.
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Pooled MCID estimates
The weighted MCID estimates were 0.52 (CCQ), 3.29 (CAT) and
7.91 (SGRQ). Results for the domains were 0.51 (symptoms), 0.61
(functional status) and 0.72 (mental) for CCQ, and 13.12
(symptoms), 8.30 (activities) and 9.09 (impact) for SGRQ. Results
from all approaches are visualised in Figure 1a–c (see also online
Supplementary Table 2).
Power analysis
Post hoc analysis demonstrates the power of the study to be over
90% based upon the number of cases (N= 451), α 0.05 and effect
sizes for CCQ (0.50), CAT (0.43) and SGRQ (0.53).
DISCUSSION
Main ﬁndings
The use of anchor- and distribution-based methods in this study
resulted in MCID ranges of 0.28–0.62 for CCQ, 1.46–6.43 for CAT
and 5.20–10.19 for SGRQ. The pooled MCID estimates derived
from the various methods in this study (0.52 for CCQ, 3.29 for CAT
and 7.91 for SGRQ) are similar or slightly higher compared with
the literature. In general, results from the patient-referencing
method were somewhat comparable to criterion- and
questionnaire-referencing. The adjusted MCID cut-off points of
the anchors (SGRQ=7.00, CCQ= 0.50 and CAT= 3.00) in the
questionnaire-referencing approach had slightly better correspon-
dence with patient- and criterion-referencing. The distribution-
based method 0.5s.d. was best comparable to anchor-based
results. The SEM was inconsistent, and the 1.96SEM was much
more conservative for CAT and SGRQ, although not for CCQ.
Interpretation of ﬁndings in relation to previously published work
The pooled MCID estimate for the CCQ in our study (0.52) is
slightly higher than the literature estimate. Patient- and criterion-
referencing in our study used comparable methodology,16,18 but
resulted in more conservative estimates. Differences in partici-
pants’ age, baseline CCQ score and period of measurement
possibly inﬂuenced this. Our study included younger patients with
more severe baseline scores. Furthermore, exacerbations might
not be a minor event for the included patients. Questionnaire-
referencing resulted in ranges of 0.28–0.60 (SGRQ anchor) and
0.42–0.61 (CAT anchor), which to some extent matched the results
of Kon et al.17 for COPD, as well as of Canavan et al. for other
respiratory diseases.18 With regard to the distribution-based
methods, the 1.96SEM and 0.5s.d. were best comparable to
results from anchor-based approaches, but slightly higher than
the results of Kocks et al.16 The 0.5s.d. matched earlier results.17,18
Domain MCID scores are approximately equivalent to MCID
estimates of the total CCQ score, although the mental domain
was higher possibly because of ﬂoor and ceiling effects in the
current study.
Almost all MCID estimates including the pooled estimate (3.29)
for CAT were higher than the suggested two points in the
literature. Patient-referencing resulted in a much higher estimate
compared with Dodd et al.21 and Kon et al.20, who used both a
GRC with just ﬁve anchor questions. Preferably, more answering
options on the anchor question should be used to provide the full
spectrum.26 Criterion-referencing in our study was comparable to
other anchor-based approaches. This method has not been
performed for the CAT before. Questionnaire-referencing resulted
in ranges of 1.46–3.00 (SGRQ anchor) and 2.14–3.08 (CCQ anchor).
The use of the original MCID of the SGRQ as anchor provided the
lowest estimates for the CAT, just as for CCQ. Possibly, the MCID of
the SGRQ is not as solid as claimed. The ranges found in our study
matched results from Kon et al.,20 but they are higher than the two
points summarised. Earlier, CAT has been mapped to the SGRQ,
resulting in an MCID of 1.60.5,21 It seems that this derived from
multiplication of the SGRQ MCID with a factor 40/100, which is
rather unusual. A similar exercise for CCQ would result in an MCID
of 0.24, far below current estimates. The distribution-based
methods SEM and 0.5s.d. matched results from anchor-based
approaches. The 1.96SEM is much higher and lacked
correspondence.
All MCID estimates for SGRQ were higher than the four points
from the literature.22 MCIDs of the domain scores on the SGRQ
(except for symptoms) seemed comparable to the estimate for the
total score. The suggested literature MCID of the SGRQ originates
from patient-referencing in two studies, featuring the use of
Salmeterol in COPD and Nedocromil Sodium in Asthma,27,28 in
which a limited ﬁve-point GRC scale was used to review therapy
effects.23 Osman et al. report the results of criterion-referencing
comparing SGRQ scores between patients re-admitted within
12 months and those who were not, resulting in an MCID estimate
of 4.8029. The results in the current study are double the original
MCID estimates, which date back to the nineties. Differences in
study setting, age of patients, time period of measurement and
different health event criterion may have inﬂuenced this large
difference. Poor methodologic quality of the patient-referencing
approach might be another explanation.
Questionnaire-referencing provided ranges of 6.98–9.47 (CAT
anchor) and 6.86–8.90 (CCQ anchor), which is somewhat compar-
able to patient- and criterion-referencing. MCID estimates from
the adjusted questionnaire-referencing approach were slightly
higher and better comparable to the other anchor-based
approaches. Upon development of the SGRQ, a hypothesised
multivariate model estimated a 6% mean difference on the 6MWD
(22 m) to be equivalent to four points on the SGRQ.6 However,
nowadays the MCID of the 6MWD is considered to be doubled30.
Schünemann et al. found a change of 3.05 on the SGRQ to match
the MCID of the CRQ dyspnoea domain;31 however, this is only a
measure for dyspnoea and not the complete health status
concept. It could have underestimated the MCID of the SGRQ
severely. Recently, a study by Welling et al. suggested the MCID of
the SGRQ to be over seven points for severe COPD patients
undergoing bronchoscopic lung volume reduction using both
anchor-based methods and distribution-based methods.24 Our
current study includes moderate to very severe COPD patients in
pulmonary rehabilitation. However, the results overlap one
another using different anchors.
The SEM and 0.5s.d. for the SGRQ are both lower than the
anchor-based results, whereas the 1.96SEM was higher and lacked
correspondence too. Tsiligianni et al.19 calculated the 1.96SEM of
the SGRQ to be 4.84, which is substantially lower than all estimates
here. Jones argued that distribution-based methods were not
applicable to SGRQ, as they lack agreement with anchor-based
approaches, and determined a standard error of the estimate (1.3)
and 0.5s.d. (8.4) based upon averaging data from 11 studies.22
However, this pooled 0.5s.d. matched with results in our study.
Strengths and limitations of this study
This study applied for the ﬁrst time multiple approaches to
determine the MCID of the CCQ, CAT and SGRQ simultaneously in
one strong data set from pulmonary rehabilitation. It is also the
ﬁrst study to include estimates of the possible MCIDs for domain
scores of the CCQ and SGRQ as well. Estimates are valid for
improvement and for patients with moderate to very severe COPD
(GOLD II–IV). No patients with wild COPD (GOLD I) were included
in this study. During PR too few patients deteriorated (n= 12) to
analyze the MCID for deterioration. MCIDs for improvement and
deterioration may differ.13
Our current study has applied an ambiguous anchor-based
method of questionnaire-referencing. However, this approach is
widely used and accepted elsewhere to estimate another
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instrument’s MCID.17,18,20 The pooled thresholds for clinically
relevant change of the CCQ, CAT and SGRQ in our study
(CCQ= 0.52, CAT = 3.29 and SGRQ=7.91) seem different from
values reported in the literature (CCQ=0.40, CAT = 2.00 and
SGRQ=4.00). This has had impact on the questionnaire-
referencing results. Averaged MCID estimates from patient-
referencing, criterion-referencing and distribution-based methods
were therefore included in the analysis as cut-off values for the
anchor’s MCID. The revised MCIDs of the anchor questionnaires
had better correspondence with results from these other
approaches. It highlights that careful selection of anchors should
be considered.
A limitation of the current study is that the correlations between
CAT, CCQ, SGRQ, and the GRC scale were below the lower limit to
be appropriate as anchor (r⩾ 0.50). Other studies using a GRC
seldom published correlation coefﬁcients, making it unclear
whether this problem is widespread. Another limitation of this
study is that the PR period was three weeks, whereas the SGRQ has
a recall period of one month and the CCQ has a recall period of one
week. A study by Meguro et al.32 compared the shorter SGRQ-C
without recall period with the original SGRQ with a speciﬁed 4-
week recall period. No differences in scores between both
questionnaires were observed. We therefore expect little inﬂuence
of the recall period on our MCID results. Last, exacerbations during
PR were used as criteria to estimate the MCID. The estimates from
this approach are higher for CCQ and SGRQ compared with other
methods. This might indicate that exacerbations were not a minor
clinically relevant event for patients.
Implications for future research, policy and practice
Our study demonstrated that the existing MCIDs of the SGRQ and
possibly of the CAT are set too low in current practice. Using a low
threshold could lead to overestimation of treatment effects.
Patients currently considered to experience clinically relevant
change as a result of treatment may in fact not experience this. On
the other hand, a more conservative cut-off point may not
approve therapy, although beneﬁts for the patient do exist. Even
though the current study adds to the body of evidence, the
analysis is based on one patient group only, where many would
be preferred. More studies are necessary to build a more complete
body of evidence and understanding, preferably with the full
scope of approaches and in different patient groups. These should
also further investigate whether the MCID for the domain scores
for the CCQ and SGRQ is comparable to the total score estimate.
The quest in ﬁnding the gold standard for an MCID in health
status tools must continue.
Conclusion
The current study suggests that improvements exceeding 0.40
points on the CCQ, 3.00 points on the CAT and 7.00 points on the
SGRQ should be considered clinically relevant for moderate to
very severe COPD patients. The MCID for domain scores on the
SGRQ and CCQ seems to be equivalent to these thresholds.
MATERIALS AND METHODS
Study subjects
This study is a secondary analysis of a subsample from the Routine
Inspiratory Muscle Training within COPD Rehabilitation (RIMTCORE) real-life
randomised controlled trial (#DRKS00004609) in the Klinik Bad Reichenhall,
Center for Rehabilitation, Pulmonology and Orthopaedics in Germany.25
COPD patients with GOLD II–IV ⩾ 18 years, who gave informed consent,
were included between February 2013 and July 2014. Exclusion criteria
were lack of linguistic or cognitive abilities to ﬁll out questionnaires;
hyperkapnic respiratory failure with a PaCO2450 mm Hg at rest or
indication for intermittent noninvasive ventilation; contraindications for
IMT (e.g., a history of recent lung surgery, fresh pulmonary embolism and
history of recurrent spontaneous pneumothorax); and other severe co-
morbid diseases that confer signiﬁcantly greater morbidity than COPD
(e.g., active cancer without successfully completed curative therapy).
Patients participated in an intensive 3-week full-day inpatient rehabilita-
tion program. The therapy components were tailored to the patients’
individual needs and included endurance and strength training, patient
education, respiratory physiotherapy, psychological support, tobacco
cessation and dietary counselling. The RIMTCORE trial was approved by
the Ethik-Kommission der Bayerischen Landesärztekammer (#12107) and
registered in the German Clinical Trial Register.
Study design and data collection
For the current MCID study, completed data were analysed at pre (T0)- and
post-inpatient rehabilitation (T1) from a subset of participants without
other respiratory co-morbidities (e.g., bronchiectasis, asthma, history of
bronchial carcinoma, sarcoidosis and tuberculosis) or alpha-1-antitrypsin
deﬁciency. On all measurement occasions, parameters collected were the
CCQ (weekly version), CAT (no recall period) and SGRQ (monthly version).
The CCQ consists of 10 items divided over three subdomains. Item scores
range from 0 to 6 (0—no impairment and 6—maximum impairment), with
the total score derived from adding up item scores and dividing by 10.4
The CAT is an eight-item one-dimensional scale with item scores ranging
from 0 to 5 (0—no impairment and 5—maximum impairment) and a total
score of 0–40.5 The SGRQ has 50 items divided over three domains with a
total score of 0–100 (0—no impairment, 100—maximum impairment).6 A
GRC anchor question ranging from − 7 to +7 was issued at T1, which
required patients to assess their global health in relation to COPD
compared with T0. Patient characteristics, post-bronchodilator spirometry,
6MWD and exacerbations in the 12 months before PR were available too.
Determining the MCID: anchor-based approaches
Patient-referencing. Changes on the CCQ, CAT and SGRQ were cate-
gorised according to the GRC score. Scores of 0 and ± 1 represented no or
hardly any change; scores of ± 2 and ± 3 were considered minimal clinically
relevant change; scores of ± 4 and ± 5 were considered moderate change;
and scores of ± 6 and ±7 were considered major change, as exempliﬁed by
Juniper et al.33 The MCID was established by calculating the mean health
status change score of the patients with a minimal clinically relevant
change on the GRC (±2 and ± 3).
Criterion-referencing. The health event exacerbation during PR was used
as an anchor, which was deﬁned as worsening of COPD symptoms
requiring at least treatment with oral corticosteroids and antibiotics. The
difference in baseline score between patients experiencing an exacerba-
tion and those without represented the MCID.
Questionnaire-referencing. Change in one instrument was anchored
against change in the other two instruments, as performed earlier.17,20
Correlations between change scores were assessed, needing to be ⩾ 0.50
to be eligible as anchor.10 The MCID of the anchor from the literature was
used as reference (CCQ=0.40, CAT= 2.00 and SGRQ= 4.00).16,17,20,22 First,
scatter plots and regression analysis with the anchor change score as the
independent variable were produced. Second, the mean was calculated for
patients achieving or failing the anchor’s MCID. Last, receiver operating
characteristics curves were plotted to identify the best change in health
status to discriminate between those achieving the anchor’s MCID and
those failing to achieve it.8 This process resulted in three estimates per
anchor. The steps were repeated if the MCID estimates derived from
patient-referencing, criterion-referencing and the distribution-based meth-
ods were different compared with the literature.
Determining the MCID: distribution-based approaches
The SEM seeks correlation between single standard error units and
established MCID estimates.12 It is calculated as SEM= σx √1− rxx, with
rxx = the intra class coefﬁcient and σx = standard deviation baseline. Both
the SEM and 1.96SEM were calculated, as there is no consensus on which
represents the MCID best. The 0.5s.d. was determined as an equivalent of
the MCID.8,11
Data analysis
Data analysis was performed using SPSS20.0 (IBM, Chicago, IL, USA).
Descriptive data were evaluated at T0 for frequencies and percentage, or
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mean and s.d. Health status data at T0 and T1 were evaluated with mean
and s.d., and tested for signiﬁcance of change with paired t-tests or
Wilcoxon signed-rank tests depending on normality of distribution. Health
status scores of CCQ, CAT and SGRQ were checked for ﬂoor- and ceiling
effects, which were deﬁned as less than 15% of the participants scoring in
the bottom and top 10% of the maximum scale score.
Patient-referencing approach. Correlations between GRC and CCQ, CAT or
SGRQ were assessed using Spearman's coefﬁcients. Participants were
classiﬁed according to the GRC score. Signiﬁcance of change was
calculated with paired t-tests or Wilcoxon signed-rank tests depending
on normality.
Criterion-referencing approach. The difference in baseline score between
patients with and without an exacerbation during PR was evaluated using
unpaired t-tests or Mann–Whitney U tests depending on normality.
Questionnaire-referencing. Correlations were assessed using Pearson's or
Spearman's coefﬁcients depending on normality. First, scatter plots and
regression analysis were performed with the anchor variable as the
independent variable. Next, mean change scores of the CCQ, CAT and
SGRQ were calculated for those achieving or failing the suggested MCID of
the anchors. Receiver operating characteristics curves were plotted with
the anchor’s MCID as the dichotomising variable. The optimal value was
selected with speciﬁcity and sensitivity preferably both ⩾ 0.70, favouring
sensitivity.
Distribution-based methods. The SEM, 1.96SEM and 0.5s.d. of the change
for each instrument were calculated. intra class coefﬁcient values were
obtained from the literature: 0.94 (CCQ), 0.80 (CAT) and 0.91 (SGRQ).4–6
Pooled MCID estimates. The mean estimates for the CCQ, CAT and SGRQ
derived from patient-referencing, criterion-referencing, questionnaire-
referencing, the SEM and 0.5s.d. were multiplied with a factor 1/5 each
to calculate a pooled average. Domain scores were averaged based on
patient- and criterion-referencing results.
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